Counter‐regulatory hormone responses to hypoglycaemia in people with type 1 diabetes after 4 weeks of treatment with liraglutide adjunct to insulin: a randomized, placebo‐controlled, double‐blind, crossover trial
- 20 May 2015
- journal article
- research article
- Published by Wiley in Diabetes, Obesity and Metabolism
- Vol. 17 (8) , 742-750
Abstract
Aims: To investigate the effect of glucagon‐like peptide 1 receptor agonist liraglutide on the counter‐regulatory hormone response to hypoglycaemia in type 1 diabetes. Methods: We conducted a randomized, double‐blind, placebo‐controlled, single‐centre trial, in which a total of 45 adults with type 1 diabetes [mean ± standard deviation age 34.5 ± 11.2 years, BMI 23.9 ± 2.4 kg/m 2 , glycated haemoglobin ( HbA1c ) 7.6 ± 0.8%, diabetes duration 16.6 ± 9.4 years] underwent a hypoglycaemic clamp after 4 weeks' crossover treatment with once‐daily liraglutide/placebo added to insulin in one of three liraglutide dose groups: 0.6 mg (n = 15); 1.2 mg (n = 14); and 1.8 mg (n = 16). The main outcome measure was glucagon concentration at nadir plasma glucose (2.5 mmol/l). Clinical outcomes were also evaluated. Five participants were withdrawn from the trial; three because of adverse events. All participants were included in the analysis. Results: Glucagon concentration at nadir plasma glucose was modest, trending towards lower concentrations at increasing liraglutide dose versus placebo: 34.7 versus 38.1 pg/ml, p = 0.555 (0.6 mg); 28.8 versus 37.2 pg/ml, p = 0.126 (1.2 mg); and 28.4 versus 37.5 pg/ml, p = 0.092 (1.8 mg). There was no difference, however, between liraglutide and placebo in incremental change in glucagon during hypoglycaemia. Other counter‐regulatory hormone levels increased during hypoglycaemia with no systematic differences between groups. Glucose infusion rates were significantly lower with liraglutide versus placebo during the clamp. After 4 weeks' treatment, HbA1c remained unchanged in the liraglutide and placebo groups. Greater reductions in insulin dose and body weight were seen with liraglutide versus placebo. Conclusions: Liraglutide did not compromise hypoglycaemic responses in type 1 diabetes after 4 weeks' treatment.Keywords
This publication has 30 references indexed in Scilit:
- Effects of exenatide and liraglutide on heart rate, blood pressure and body weight: systematic review and meta-analysisBMJ Open, 2013
- The physiology and pathophysiology of the neural control of the counterregulatory responseAmerican Journal of Physiology-Regulatory, Integrative and Comparative Physiology, 2012
- Liraglutide as additional treatment for type 1 diabetesEuropean Journal of Endocrinology, 2011
- Four Weeks of Treatment With Liraglutide Reduces Insulin Dose Without Loss of Glycemic Control in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes Care, 2011
- Antidiabetic Actions of Endogenous and Exogenous GLP-1 in Type 1 Diabetic Patients With and Without Residual β-Cell FunctionDiabetes, 2011
- Hypoglycemia in Type 1 Diabetes MellitusEndocrinology and Metabolism Clinics of North America, 2010
- Temporal patterns in overweight and obesity in Type 1 diabetesDiabetic Medicine, 2010
- The Barrier of Hypoglycemia in DiabetesDiabetes, 2008
- Glucagonostatic Actions and Reduction of Fasting Hyperglycemia by Exogenous Glucagon-Like Peptide I(7–36) amide in type I diabetic patientsDiabetes Care, 1996
- Hypoglycemia-associated autonomic failure in insulin-dependent diabetes mellitus. Recent antecedent hypoglycemia reduces autonomic responses to, symptoms of, and defense against subsequent hypoglycemia.Journal of Clinical Investigation, 1993